New hope for hard-to-treat melanoma? drug combo tested in small trial
NCT ID NCT05764395
First seen Apr 29, 2026 · Last updated Apr 30, 2026 · Updated 1 time
Summary
This study tests whether adding rigosertib to pembrolizumab can help people with advanced melanoma that no longer responds to standard immunotherapy. The trial enrolled 7 adults with unresectable or metastatic melanoma. Researchers are measuring how many patients' tumors shrink or stop growing, and tracking side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.